ESMO 2021 Coverage
Every year, the European Society for Medical Oncology Congress brings together clinicians, researchers, and advocates to discuss the latest cancer study results. We're proud to present our coverage below.
Comments
-
Adding Carboplatin to Chemotherapy Before Surgery Improves Early-Stage Triple-Negative Breast Cancer Outcomes
September 20, 2021
Adding carboplatin (brand name: Paraplatin) to the standard neoadjuvant chemotherapy regimen for early-stage triple-negative breast cancer improved event-free survival. Read more... -
Enhertu Dramatically More Effective Than Kadcyla as Second Treatment for Metastatic HER2-Positive Breast Cancer
September 22, 2021
Enhertu more than doubled the 12-month progression-free survival rate than Kadcyla in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated. Read more... -
After 2-3 Years of Tamoxifen, 5 Years of Femara Offers More Benefits Than 2-3 Years
September 30, 2021
After taking tamoxifen for 2 to 3 years following surgery, postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer had a better survival rate from taking 5 years of Femara rather than 2 to 3 years of Femara. Read more... -
Adding Kisqali to Femara Improves Overall Survival for Postmenopausal Women With Advanced-Stage Hormone-Receptor-Positive HER2-Negative Breast Cancer
October 5, 2021
Adding Kisqali to Femara as a first treatment for advanced-stage hormone-receptor-positive HER2-negative breast cancer in postmenopausal women improved overall survival by more than 1 year. Read more... -
Experimental Vic-Trastuzumab Duocarmazine Better Than Doctors' Treatment Choices for Pre-treated Advanced-Stage HER2-Positive Breast Cancer
October 5, 2021
The experimental targeted therapy medicine vic-trastuzumab duocarmazine improved progression-free survival and overall survival more than doctors' treatment choice for people diagnosed with advanced-stage HER2-positive breast cancer that had been previously treated with anti-HER2 medicine. Read more... -
Adding Keytruda to Chemotherapy Improves Overall Survival in Metastatic, Strongly PD-L1-Positive Triple-Negative Breast Cancer
October 5, 2021
Adding the immunotherapy medicine Keytruda to chemotherapy improved overall survival more than chemotherapy alone in people diagnosed with metastatic triple-negative, strongly PD-L1-positive breast cancer, according to the KEYNOTE-355 study's final results. Read more... -
Long-Term Side Effects Reduce Quality of Life Years After Cancer Diagnosis
October 5, 2021
About 4 years after being diagnosed with cancer, 14% of disease-free survivors were dissatisfied with the care they received for ongoing, long-term side effects of cancer treatment. Read more... -
Breast Cancer Research at ESMO 2021
October 21, 2021
Dr. Brian Wojciechowski practices medical oncology in Delaware County, Pennsylvania at Riddle, Taylor, and Crozer hospitals and also serves as Breastcancer.org's medical adviser. A native of South Philadelphia, he trained at Temple University School of Medicine and Lankenau Medical Center. Dr. Wojciechowski is a sought-after speaker on the topics of medical ethics and the biology of cancer.
Dr. Wojciechowski joined us to talk about some of the most notable research at the European Society for Medical Oncology Congress 2021.
Listen to the episode to hear Dr. Wojciechowski explain:
- what an antibody-drug conjugate is
- results from the DESTINY-Breast03 study, showing Enhertu more than doubled the 12-month progression-free survival rate compared to Kadcyla in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated
- results from the BrighTNess study, showing adding carboplatin to chemotherapy before surgery improves progression-free survival.
Running time: 14:09
-
October 1, 2021
Dr. Gabriel Hortobagyi is professor of breast medical oncology at the University of Texas MD Anderson Cancer Center. He is a past president of the American Society of Clinical Oncology and is one of the world's leading authorities on breast cancer treatment. He has published more than 1,000 papers in peer-reviewed journals.
At the European Society for Medical Oncology Congress 2021, Dr. Hortobagyi presented overall survival results from the MONALEESA-2 trial, which compared the combination of Kisqali and Femara to Femara alone to treat advanced-stage hormone-receptor-positive HER2-negative breast cancer in postmenopausal women. Earlier results from the study found that adding Kisqali to Femara improved progression-free survival — the amount of time the women lived without the cancer growing. These new results found that the combination of Kisqali and Femara also improved overall survival — the length of time women lived whether the cancer grew or not.
Listen to the episode to hear Dr. Hortobagyi explain:
- the goals of the MONALEESA-2 study
- why the overall survival difference of more than 1 year is so important
- whether the improvement in overall survival is likely to be the same no matter which aromatase inhibitor is used
- what the results mean for postmenopausal women diagnosed with advanced-stage hormone-receptor-positive HER2-negative breast cancer
Running time: 19:47
Listen now or read the transcript. -
September 24, 2021
Dr. Hope Rugo is professor of medicine in the division of hematology and oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, where she is also the director of breast oncology and clinical trials education. Dr. Rugo is also a member of the Breastcancer.org Professional Advisory Board. She is a principal investigator of a number of clinical trials looking at combining new targeted and immunotherapy medicines with standard treatments for both early-stage and advanced-stage breast cancer and has published hundreds of peer-reviewed papers.
At the European Society for Medical Oncology Congress 2021, Dr. Rugo presented final results from the KEYNOTE-355 trial, which was looking to see if Keytruda (chemical name: pembrolizumab) and chemotherapy were better than chemotherapy alone as a first treatment for metastatic PD-L1-positive, triple-negative breast cancer. Earlier results found that adding Keytruda to chemotherapy improved progression-free survival — how long people lived before the cancer grew — for this type of breast cancer. These new results show that adding Keytruda improves overall survival — how long people live whether the breast cancer grows or not.
Listen to the podcast to hear Dr. Rugo explain:
- what the KEYNOTE-355 aimed to do
- whether Keytruda offers benefits for PD-L1-negative disease
- why it's important for a medicine to improve overall survival as well as progression-free survival
- the differences in PD-L1 tests and what they mean for the effectiveness of breast cancer checkpoint inhibitor medicines
Running time: 25:03
Listen now or read the transcript.
Categories
- All Categories
- 679 Advocacy and Fund-Raising
- 289 Advocacy
- 68 I've Donated to Breastcancer.org in honor of....
- Test
- 322 Walks, Runs and Fundraising Events for Breastcancer.org
- 5.6K Community Connections
- 282 Middle Age 40-60(ish) Years Old With Breast Cancer
- 53 Australians and New Zealanders Affected by Breast Cancer
- 208 Black Women or Men With Breast Cancer
- 684 Canadians Affected by Breast Cancer
- 1.5K Caring for Someone with Breast cancer
- 455 Caring for Someone with Stage IV or Mets
- 260 High Risk of Recurrence or Second Breast Cancer
- 22 International, Non-English Speakers With Breast Cancer
- 16 Latinas/Hispanics With Breast Cancer
- 189 LGBTQA+ With Breast Cancer
- 152 May Their Memory Live On
- 85 Member Matchup & Virtual Support Meetups
- 375 Members by Location
- 291 Older Than 60 Years Old With Breast Cancer
- 177 Singles With Breast Cancer
- 869 Young With Breast Cancer
- 50.4K Connecting With Others Who Have a Similar Diagnosis
- 204 Breast Cancer with Another Diagnosis or Comorbidity
- 4K DCIS (Ductal Carcinoma In Situ)
- 79 DCIS plus HER2-positive Microinvasion
- 529 Genetic Testing
- 2.2K HER2+ (Positive) Breast Cancer
- 1.5K IBC (Inflammatory Breast Cancer)
- 3.4K IDC (Invasive Ductal Carcinoma)
- 1.5K ILC (Invasive Lobular Carcinoma)
- 999 Just Diagnosed With a Recurrence or Metastasis
- 652 LCIS (Lobular Carcinoma In Situ)
- 193 Less Common Types of Breast Cancer
- 252 Male Breast Cancer
- 86 Mixed Type Breast Cancer
- 3.1K Not Diagnosed With a Recurrence or Metastases but Concerned
- 189 Palliative Therapy/Hospice Care
- 488 Second or Third Breast Cancer
- 1.2K Stage I Breast Cancer
- 313 Stage II Breast Cancer
- 3.8K Stage III Breast Cancer
- 2.5K Triple-Negative Breast Cancer
- 13.1K Day-to-Day Matters
- 132 All things COVID-19 or coronavirus
- 87 BCO Free-Cycle: Give or Trade Items Related to Breast Cancer
- 5.9K Clinical Trials, Research News, Podcasts, and Study Results
- 86 Coping with Holidays, Special Days and Anniversaries
- 828 Employment, Insurance, and Other Financial Issues
- 101 Family and Family Planning Matters
- Family Issues for Those Who Have Breast Cancer
- 26 Furry friends
- 1.8K Humor and Games
- 1.6K Mental Health: Because Cancer Doesn't Just Affect Your Breasts
- 706 Recipe Swap for Healthy Living
- 704 Recommend Your Resources
- 171 Sex & Relationship Matters
- 9 The Political Corner
- 874 Working on Your Fitness
- 4.5K Moving On & Finding Inspiration After Breast Cancer
- 394 Bonded by Breast Cancer
- 3.1K Life After Breast Cancer
- 806 Prayers and Spiritual Support
- 285 Who or What Inspires You?
- 28.7K Not Diagnosed But Concerned
- 1K Benign Breast Conditions
- 2.3K High Risk for Breast Cancer
- 18K Not Diagnosed But Worried
- 7.4K Waiting for Test Results
- 603 Site News and Announcements
- 560 Comments, Suggestions, Feature Requests
- 39 Mod Announcements, Breastcancer.org News, Blog Entries, Podcasts
- 4 Survey, Interview and Participant Requests: Need your Help!
- 61.9K Tests, Treatments & Side Effects
- 586 Alternative Medicine
- 255 Bone Health and Bone Loss
- 11.4K Breast Reconstruction
- 7.9K Chemotherapy - Before, During, and After
- 2.7K Complementary and Holistic Medicine and Treatment
- 775 Diagnosed and Waiting for Test Results
- 7.8K Hormonal Therapy - Before, During, and After
- 50 Immunotherapy - Before, During, and After
- 7.4K Just Diagnosed
- 1.4K Living Without Reconstruction After a Mastectomy
- 5.2K Lymphedema
- 3.6K Managing Side Effects of Breast Cancer and Its Treatment
- 591 Pain
- 3.9K Radiation Therapy - Before, During, and After
- 8.4K Surgery - Before, During, and After
- 109 Welcome to Breastcancer.org
- 98 Acknowledging and honoring our Community
- 11 Info & Resources for New Patients & Members From the Team